Israel Englander’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-49,557
Closed -$105K 4522
2018
Q3
$105K Buy
+49,557
New +$119K ﹤0.01% 3730
2018
Q2
Sell
-232,774
Closed -$740K 4470
2018
Q1
$740K Sell
232,774
-310,561
-57% -$856K ﹤0.01% 2849
2017
Q4
$2.23M Buy
543,335
+324,845
+149% +$1.41M ﹤0.01% 2216
2017
Q3
$988K Sell
218,490
-64,175
-23% -$260K ﹤0.01% 2515
2017
Q2
$941K Buy
282,665
+52,858
+23% +$219K ﹤0.01% 2471
2017
Q1
$2.12M Sell
229,807
-85,912
-27% -$754K ﹤0.01% 1977
2016
Q4
$2.43M Sell
315,719
-335,754
-52% -$3.08M 0.01% 1765
2016
Q3
$7.45M Buy
651,473
+221,780
+52% +$2.58M 0.01% 1098
2016
Q2
$5.29M Buy
429,693
+382,337
+807% +$4.64M 0.01% 1228
2016
Q1
$479K Buy
+47,356
New +$556K ﹤0.01% 2540
2015
Q4
Sell
-120,000
Closed -$1.99M 4114
2015
Q3
$1.99M Buy
+120,000
New +$2.41M ﹤0.01% 1905
2014
Q4
Sell
-13,001
Closed -$246K 4618
2014
Q3
$246K Buy
13,001
+1,601
+14% +$32.2K ﹤0.01% 3250
2014
Q2
$266K Sell
11,400
-17,360
-60% -$429K ﹤0.01% 2950
2014
Q1
$968K Buy
+28,760
New +$969K ﹤0.01% 2246
2013
Q4
Sell
-45,466
Closed -$696K 4162
2013
Q3
$696K Buy
+45,466
New +$842K ﹤0.01% 2347

Other funds holding OMED

Israel Englander's OMED Position: Q4 2018 in Review

Israel Englander sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2018, closing a stake of 49,557 shares — an estimated $105K sold.

Israel Englander first reported a position in OMED in Q3 2013 and held it in 15 quarters. The position peaked at $7.45M in Q3 2016. 42 funds tracked by Wall St. Rank hold OMED as of Q4 2018.

  • Israel Englander reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Israel Englander sold 49,557 OncoMed Pharmaceuticals, Inc. shares in Q4 2018, an estimated $105K.
  • Israel Englander first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2013 and held it in 15 quarters.
  • Israel Englander's OncoMed Pharmaceuticals, Inc. position peaked at $7.45M in Q3 2016.
  • 42 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2018.

Based on Millennium Management's 13F filing for Q4 2018, filed 14 Feb 2019.